DROLOXIFENE IN THE TREATMENT OF METASTATIC BREAST-CANCER

被引:0
作者
KREIENBERG, R
机构
来源
ONKOLOGIE | 1994年 / 17卷
关键词
DROLOXIFENE; ANTIESTROGENS; METASTATIC BREAST CANCER; PRETREATED PATIENTS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
206 postmenopausal women with metastatic breast cancer from 16 European and Brasilian centers were treated with either 20, 40 or 100 mg Droloxifene until disease progression. 69% of the patients had been pretreated with other hormonal agents, chemotherapy, or both. Response rates from intention-to-treat analyses were 16% in the 20-mg group (n=68), 19% in the 40-mg group (n=81), and 14% in the 100-mg group (n=57). Time to disease progression was 4.5 months in the 20-mg group, 4.6 months in the 40-mg group, and 4.4 months in the 100-mg group. For the response rate and the time to progression no statistically significant differences between dose groups were found. Tolerability was equally good for all dose groups.
引用
收藏
页码:40 / 44
页数:5
相关论文
共 50 条
  • [21] Optimizing the treatment of metastatic breast cancer
    Julie R. Gralow
    Breast Cancer Research and Treatment, 2005, 89 : S9 - S15
  • [22] Taxanes for the Treatment of Metastatic Breast Cancer
    Gradishar, W. J.
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2012, 6 : 159 - 171
  • [23] Pertuzumab for the treatment of metastatic breast cancer
    Langdon, Simon P.
    Cameron, David A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (08) : 907 - 918
  • [24] PHASE-II TRIAL OF CARBOPLATIN AND ETOPOSIDE IN METASTATIC BREAST-CANCER
    CROWN, J
    HAKES, T
    REICHMAN, B
    LEBWOHL, D
    GILEWSKI, T
    SURBONE, A
    CURRIE, V
    YAO, TJ
    HUDIS, C
    SEIDMAN, A
    NORTON, L
    CANCER, 1993, 71 (04) : 1254 - 1257
  • [25] EVALUATION OF PIROXANTRONE IN WOMEN WITH METASTATIC BREAST-CANCER AND FAILURE ON NONANTHRACYCLINE CHEMOTHERAPY
    INGLE, JN
    KUROSS, SA
    MAILLIARD, JA
    LOPRINZI, CL
    JUNG, SH
    NELIMARK, RA
    KROOK, JE
    LONG, HJ
    CANCER, 1994, 74 (06) : 1733 - 1738
  • [26] CHEMOTHERAPY WITH MITOMYCIN-C AND VINBLASTINE IN PRETREATED METASTATIC BREAST-CANCER
    PERRONE, F
    DEPLACIDO, S
    CARLOMAGNO, C
    NUZZO, F
    RUGGIERO, A
    DELAURENTIIS, M
    GRIDELLI, C
    PAGLIARULO, C
    BIANCO, AR
    TUMORI, 1993, 79 (04) : 254 - 257
  • [27] A PHASE-II TRIAL OF VINORELBINE AND THIOTEPA IN METASTATIC BREAST-CANCER
    FABI, A
    TONACHELLA, R
    SAVARESE, A
    CIRULLI, S
    TOMAO, S
    CONTE, E
    COGNETTI, F
    ANNALS OF ONCOLOGY, 1995, 6 (02) : 187 - 189
  • [28] DEVELOPMENT AND VALIDATION OF PROGNOSTIC MODELS IN METASTATIC BREAST-CANCER - A GOCS STUDY
    RABINOVICH, M
    VALLEJO, C
    BIANCO, A
    PEREZ, J
    MACHIAVELLI, M
    LEONE, B
    ROMERO, A
    RODRIGUEZ, R
    CUEVAS, M
    DANSKY, C
    XYNOS, F
    ALVAREZ, L
    ONCOLOGY, 1992, 49 (03) : 188 - 195
  • [29] Lapatinib and ixabepilone for the treatment of metastatic breast cancer
    Halterman, Patti A.
    PHARMACOTHERAPY, 2008, 28 (10): : 1255 - 1266
  • [30] Profile of palbociclib in the treatment of metastatic breast cancer
    Ehab, Moataz
    Elbaz, Mohamad
    BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 83 - 91